Screener
Bio-Rad Laboratories BIO Clinical Diagnostics — Gross Profit
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bio-Rad Laboratories in its filing.
Tagged under the XBRL concept us-gaap:GrossProfit.
The source filing: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:19 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000012208-26-000035
FAQ
- What is Bio-Rad Laboratories's clinical diagnostics — gross profit?
- Bio-Rad Laboratories (BIO) reported clinical diagnostics — gross profit of $181.8M in Q1 2026.
- How has Bio-Rad Laboratories's clinical diagnostics — gross profit changed year-over-year?
- Bio-Rad Laboratories's clinical diagnostics — gross profit increased by 2.4% year-over-year, from $177.6M to $181.8M.
- What is the long-term trend for Bio-Rad Laboratories's clinical diagnostics — gross profit?
- Over 3 years (2022 to 2025), Bio-Rad Laboratories's clinical diagnostics — gross profit has grown at a 1.4% compound annual growth rate (CAGR), from $754.5M to $786.8M.
- What does clinical diagnostics — gross profit mean?
- The difference between net sales and the cost of goods sold for the Clinical Diagnostics segment. It measures the profitability of the segment's core manufacturing and distribution activities before operating expenses.
Ask your AI about Bio-Rad Laboratories's clinical diagnostics — gross profit.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude